Hybrid particles derived from alendronate and bioactive glass for treatment of osteoporotic bone defects

J Mater Chem B. 2019 Feb 7;7(5):796-808. doi: 10.1039/c8tb03062f. Epub 2019 Jan 11.

Abstract

Osteoporosis is the most widespread metabolic bone disease which represents a major public health burden. Consequently, novel biomaterials with a strong capacity to regenerate osteoporotic bone defects are urgently required. In view of the anti-osteoporotic and osteopromotive efficacy of alendronate and 45S5 bioactive glass, respectively, we investigated the feasibility to synthesize novel hybrid particles by exploiting the strong interactions between these two compounds. Herein, we demonstrate the facile preparation of a novel class of hybrid particles of tunable morphology, chemical composition and structure. These hybrid particles (i) release alendronate and various inorganic elements (Ca, Na, Si, and P) in a controlled manner, (ii) exhibit a strong anti-osteoclastic effect in vitro, and (iii) stimulate regeneration of osteoporotic bone in vivo. Consequently, this novel class of hybrid biomaterials opens up new avenues of research on the design of bone substitutes with specific activity to facilitate regeneration of bone defects in osteoporotic patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alendronate / therapeutic use*
  • Biocompatible Materials / chemical synthesis
  • Biocompatible Materials / therapeutic use
  • Bone Density Conservation Agents / therapeutic use
  • Bone Regeneration*
  • Bone Substitutes / chemistry
  • Ceramics / therapeutic use*
  • Drug Design
  • Glass
  • Humans
  • Osteoporosis / therapy*

Substances

  • Biocompatible Materials
  • Bone Density Conservation Agents
  • Bone Substitutes
  • bioactive glass 45S5
  • Alendronate